Clinical Trial Update: A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan [Phase 1]

View source ↗

Summary

This Phase 1 clinical trial update describes ABBV-383 (Etentamig) being studied in adults with relapsed/refractory multiple myeloma in Japan, focusing on advers…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ABBV-383 (Etentamig)

Snippet

Sponsor: AbbVie | Conditions: Relapsed/Refractory Multiple Myeloma | Phase 1 | Status: ACTIVE_NOT_RECRUITING